{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+dose+Placebo&page=4",
    "query": {
      "intervention": "High dose Placebo",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 2058,
    "total_pages": 206,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+dose+Placebo&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+dose+Placebo&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T00:21:24.082Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05162365",
      "title": "A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "IBI314",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 248,
      "start_date": "2022-01-06",
      "completion_date": "2022-11-18",
      "has_results": false,
      "last_update_posted_date": "2023-12-18",
      "last_synced_at": "2026-11-20T00:21:24.082Z",
      "location_count": 19,
      "location_summary": "Anaheim, California • Long Beach, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05162365"
    },
    {
      "nct_id": "NCT01307917",
      "title": "Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Nephropathy",
        "Endothelial Dysfunction"
      ],
      "interventions": [
        {
          "name": "flavonoids",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Texas Tech University Health Sciences Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Years to 21 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-07",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2012-12-17",
      "last_synced_at": "2026-11-20T00:21:24.082Z",
      "location_count": 1,
      "location_summary": "Amarillo, Texas",
      "locations": [
        {
          "city": "Amarillo",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01307917"
    },
    {
      "nct_id": "NCT00343460",
      "title": "APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nausea and Vomiting",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "APF530",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Palonosetron Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Heron Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 1428,
      "start_date": "2006-06",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-11-20T00:21:24.082Z",
      "location_count": 52,
      "location_summary": "Anniston, Alabama • Glendale, Arizona • Tucson, Arizona + 46 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343460"
    },
    {
      "nct_id": "NCT05759208",
      "title": "The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OK-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Okyo Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2023-04-28",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-09",
      "last_synced_at": "2026-11-20T00:21:24.082Z",
      "location_count": 6,
      "location_summary": "Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05759208"
    },
    {
      "nct_id": "NCT02951182",
      "title": "A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "TEZ",
          "type": "DRUG"
        },
        {
          "name": "IVA",
          "type": "DRUG"
        },
        {
          "name": "VX-440",
          "type": "DRUG"
        },
        {
          "name": "Matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2016-10",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2020-08-28",
      "last_synced_at": "2026-11-20T00:21:24.082Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02951182"
    },
    {
      "nct_id": "NCT06724640",
      "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VH4011499 low dose Injection",
          "type": "DRUG"
        },
        {
          "name": "VH4011499 high dose Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 168,
      "start_date": "2024-12-16",
      "completion_date": "2028-08-16",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-11-20T00:21:24.082Z",
      "location_count": 2,
      "location_summary": "Las Vegas, Nevada • Austin, Texas",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06724640"
    },
    {
      "nct_id": "NCT02954978",
      "title": "Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Parkinsons Disease With Dementia"
      ],
      "interventions": [
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib 150mg oral capsule [Tasigna]",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib 300mg oral capsule [Tasigna]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 75,
      "start_date": "2017-01",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-11-20T00:21:24.082Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02954978"
    },
    {
      "nct_id": "NCT01037725",
      "title": "Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AZD5847",
          "type": "DRUG"
        },
        {
          "name": "Placebo to AZD5847",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 64,
      "start_date": "2009-12",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2010-07-14",
      "last_synced_at": "2026-11-20T00:21:24.082Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01037725"
    },
    {
      "nct_id": "NCT00538083",
      "title": "Cocoa and Endothelial Function in Adults With Elevated BMI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardioprotection"
      ],
      "interventions": [
        {
          "name": "Chocolate",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Griffin Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 45,
      "start_date": "2005-08",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2020-03-26",
      "last_synced_at": "2026-11-20T00:21:24.082Z",
      "location_count": 1,
      "location_summary": "Derby, Connecticut",
      "locations": [
        {
          "city": "Derby",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538083"
    },
    {
      "nct_id": "NCT01280695",
      "title": "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "MSDC-0602 100 mg",
          "type": "DRUG"
        },
        {
          "name": "MSDC-0602 250 mg",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Metabolic Solutions Development Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 129,
      "start_date": "2011-02",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2014-04-14",
      "last_synced_at": "2026-11-20T00:21:24.082Z",
      "location_count": 14,
      "location_summary": "Goodyear, Arizona • Chula Vista, California • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280695"
    }
  ]
}